Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
Phase I Study of Sequestered Transscleral, Controlled-Release Celecoxib Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous
Sponsor: Targeted Therapy Technologies, LLC
A PHASE1 clinical study on Branch Retinal Vein Occlusion and Central Serous Retinopathy With Pit of Optic Disc, this trial is ongoing. The trial is conducted by Targeted Therapy Technologies, LLC and has accumulated 8 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Unknown PHASE1
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Jan 2026 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2022 — Dec 2023 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
May 2021 — Jun 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE1
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Targeted Therapy Technologies, LLC
For direct contact, visit the study record on ClinicalTrials.gov .